ABSTRACT:
A recently approved drug eluxadoline shows promise as a treatment and management for irritable bowel syndrome-D. However, because of its low water solubility, which results in a low dissolution rate and oral bioavailability, its applications have been limited. The current study aims to cure irritable bowel syndrome by developing chitosan nanoparticles containing eluxadoline. Box-Behnken Design Expert software was used to optimize the chitosan nanoparticles loaded with eluxadoline that had been developed. Sodium tripolyphosphate was used as a cross-linking agent in the ionic gelation process to developed the Eluxadoline-loaded chitosan nanoparticles. The effects of chitosan concentration (X1), sodium tripolyphosphate concentration (X2), and sodium tripolyphosphate volume (X3) on particle size, PDI, zeta potential and entrapment efficacy from nanoparticles were investigated. The results revealed that entrapment efficiency was highest at low level of chitosan concentration, high level of Sodium tripolyphosphate concentration and low levels of Sodium tripolyphosphate volume. Based on the particle size (300.4), PDI (0.305), zeta potential (41.2mV), and entrapment efficacy (76.89%), the resulting formulation was optimized. The efficiency of the drug release from optimised formulation was studied in vitro by using a dialysis bag diffusion technique in buffer condition 6.8 pH intestinal conditions. The optimized formulation showed a sustained release behaviour with maximum drug release 80.23%. Accordingly, the results proved that the developed chitosan-based polymeric nanoparticles can act as a potential approach for the effective delivery of eluxadoline through oral administration for irritable bowel syndrome diarrhoea treatment.
Cite this article:
Manisha Dhere, Deepak Jain. Box-Behnken Designed Eluxadoline Loaded Chitosan Nanoparticles for the Treatment of Irritable Bowel Syndrome. Research Journal of Pharmacy and Technology. 2024; 17(9):4221-7. doi: 10.52711/0974-360X.2024.00652
Cite(Electronic):
Manisha Dhere, Deepak Jain. Box-Behnken Designed Eluxadoline Loaded Chitosan Nanoparticles for the Treatment of Irritable Bowel Syndrome. Research Journal of Pharmacy and Technology. 2024; 17(9):4221-7. doi: 10.52711/0974-360X.2024.00652 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-9-13
REFERENCES:
1. Md. KA, Mohammed MA, Mohammed FA, Muzaffar I. Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box–Behnken Design, and Anti-Diarrheal Activity. Pharmaceutics. 2023; 15(5): 1460. doi: 10.3390/pharmaceutics15051460.
2. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review. JAMA. 2015; 313(9): 949–958. doi: 10.1001/jama.2015.0954
3. Longstreth GF, Thompson WG, Chey WD. Functional bowel disorders. Gastroenterology. 2006; 30(5): 1480-91. doi: 10.1053/j.gastro.2005.11.061.
4. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin Gastroenterol Hepatol. 2012; 10(7): 712-721. e4.doi: 10.1016/j.cgh.2012.02.029.
5. Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017; 15(1): 35. doi: 10.1186/s12955-017-0611-2.
6. Ten Berg MJ, Goettsch WG, Van den Boom G, Smout AJ. Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. European Journal Gastroenterology Hepatology. 2006; 18(5): 475-81. doi: 10.1097/ 00042737-200605000-00004
7. Lackner JM, Ma CX, Keefer L, Brenner DM, Gudleski GD, et al. Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013; 11(9): 1147-57. doi: 10.1016/j.cgh.2013.03.011.
8. Buono JL, Mathur K, Averitt AJ, Andrae DA. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population. J Manag Care Spec Pharm. 2017; 23(4): 453-460. doi: 10.18553/ jmcp.2016.16138.
9. Canavan C, West J, Card T. Review article: The economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014; 40(9): 1023-34. doi: 10.1111/apt.12938.
10. Tornblom H, Goosey R, Wiseman G, Baker S. Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: Results from patient and healthcare professional surveys. United European Gastroenterol J. 2018; 6(9): 1417-1427. doi: 10.1177/2050640618787648.
11. Mayyas MA, Al- Remawi. Properties of chitosan nanoparticles formed using sulphate anions as crosslinking bridges. Am J Appl Sci 2012; 9(7): 1091-100. doi: https://doi.org/10.3844/ ajassp.2012.1091.1100
12. Zohri M, Gazori T, Mirdamadi S, Asadi A, Haririan I. Polymeric nanoparticles: Production, applications, and advantage. IJNT 2009; 3: 1-14. https://www.researchgate.net/publication/ 231520082
13. Coco R, Plapied L, Pourcelle V, Jérôme C, et al. Drug delivery to inflamed colon by nanoparticles: Comparison of different strategies. International Journal Pharm. 2013; 440(1): 3-12. doi: 10.1016/j.ijpharm.2012.07.017.
14. Kumar J, Newton AMJ. Rifaximin - Chitosan Nanoparticles for Inflammatory Bowel Disease (IBD). Recent Patents on Inflammation & Allergy Drug Discovery. 2016; 10(3): 1-12. doi:10.2174/1872213X10666161230111226
15. Chopra AK, Marwaha1 RK, Kaushik D, Dureja H. Box-Behnken Designed Fluconazole Loaded Chitosan Nanoparticles for Ocular Delivery. J Pharm Drug Deliv Res. 2014; 3(1): 1-6. doi:10.4172/ 2325-9604.1000121
16. N. Tara Sowjanya, R. Dhivya, K. Meenakshi, K.A. Vedhanayakisri. Potential Applications of Chitosan Nanoparticles as Novel Support in Enzyme Immobilization. Research J. Engineering and Tech., Oct.-Dec., 2013; 4(4): 288-294.
17. Uday Kumar Thummala, Eswar Guptha Maddi, Prameela Rani Avula. Optimization and development of orodispersible films for ledipasvir and sofosbuvir through solid dispersion using Box-Behnken design. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(3): 201-8. doi: 10.52711/0975-4377.2021.00036
18. Kishore Uttam Kothule, Prashant Kesharwani, Suresh Kumar Gidwani, Paraag Gide. Development and Characterization of Chitosan Nanoparticles and Improvement of Oral Bioavailability of Poorly Water Soluble Acyclovir. Research J. Pharm. and Tech., Oct.-Dec. 2010; 3(4): 1241-1245.
19. Anilkumar J. Shinde, Harinath N. More. Lovastatin Loaded Chitosan Nanoparticles: Preparation, Evaluation and In vitro Release Studies. Research J. Pharm. and Tech., Dec. 2011; 4(12): 1869-1876.
20. Chettupalli A K, Padmanabha Rao A, Kuchukuntla M, Bakshi V. Development and Optimization of Aripiprazole ODT by using box-Behnken Design. Research J. Pharm. and Tech., 2020; 13(12): 6195-6201. doi: 10.5958/0974-360X.2020.01080.X